Rishi Graham1, Harsimran Singh2, Lars Mueller2, Kirstin White2, Steph Habif2, Jordan E. Pinsker2 1University of California San Diego, San Diego, 2Tandem Diabetes Care
The Control-IQ Observational (CLIO) Study is currently an ongoing IRB-approved, single-arm, longitudinal study evaluating real-world use of Tandem’s t:slim X2 insulin pump with Control-IQ technology in people with T1D (PWT1D). Previous publications from CLIO have shown glycemic improvements in ethnically diverse groups of PWT1D after 3 months of using Control-IQ technology.
We evaluated relationships between glycemic metrics, participants’ age, and previous insulin delivery method at 9 months after CLIO study start. Participants (N=1913) who had uploaded at least 21 days of Control-IQ feature usage data to Tandem’s t:connect® web application (US only) and had ≥75% CGM use were included in the analysis. Impact of baseline factors on sensor glycemic outcomes were analyzed. Differences between baseline HbA1c and GMI were compared using a Wilcoxon test.
Baseline HbA1c (self-reported) for the overall sample was 7.4% (median, IQR=6.8-8.3). At post with Control-IQ technology, GMI reflected significant glycemic improvement (7.06%, IQR=6.75-7.42). Previous MDI users demonstrated 71.23% TIR (61.29-81.16) and overnight TIR=75.26% (64.62-84.5) while previous pump users showed TIR=70.43% (61.27-78.67) and overnight TIR=76.39(65.46-85.12). Participants aged ≥65 years, transitioning from prior pump therapy showed the lowest GMI (median=6.87, IQR=6.62-7.17) and the highest sensor time in range (TIR) (77.94%, IQR=69.29-83.8). Younger participants although reporting higher HbA1c at baseline (6–13-year-old, 7.8% (IQR=7.1-8.6); 14–17-year-old, 8% (IQR=7.1-9)) also showed significant glycemic improvements after 9 months of using Control-IQ technology (GMI=7.4 and 7.35, respectively).
Long-term use of Control-IQ technology demonstrated improved glycemic metrics irrespective of participants’ age and previous insulin delivery method.
Median Glycemic Metrics